|
US7338959B2
(en)
|
2002-03-01 |
2008-03-04 |
Smithkline Beecham Corporation |
Diamino-pyrimidines and their use as angiogenesis inhibitors
|
|
AU2003226149A1
(en)
|
2002-04-05 |
2003-10-27 |
Merck & Co., Inc. |
Substituted aryl amides
|
|
JP2006528702A
(ja)
|
2003-05-21 |
2006-12-21 |
プロシディオン・リミテッド |
グリコーゲンホスホリラーゼのピロロピリジン−２−カルボン酸アミドインヒビター
|
|
WO2006053166A1
(en)
|
2004-11-12 |
2006-05-18 |
Bristol-Myers Squibb Company |
8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
|
|
US7737279B2
(en)
|
2005-05-10 |
2010-06-15 |
Bristol-Myers Squibb Company |
1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
|
|
TW200803855A
(en)
|
2006-02-24 |
2008-01-16 |
Kalypsys Inc |
Quinolones useful as inducible nitric oxide synthase inhibitors
|
|
JP2010517970A
(ja)
|
2007-02-02 |
2010-05-27 |
ノイロサーチ アクティーゼルスカブ |
ピリジニル−ピラゾール誘導体及びカリウムチャネル調節剤としてのそれらの使用
|
|
US8865732B2
(en)
|
2008-03-21 |
2014-10-21 |
Novartis Ag |
Heterocyclic compounds and uses thereof
|
|
TWI501967B
(zh)
|
2010-12-16 |
2015-10-01 |
Janssen R&D Ireland |
作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
|
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
WO2013056679A1
(en)
|
2011-10-21 |
2013-04-25 |
Beijing Hanmi Pharmaceutical Co., Ltd |
Novel heteroaryl-amino derivatives
|
|
AR090151A1
(es)
|
2012-03-07 |
2014-10-22 |
Lilly Co Eli |
Compuestos inhibidores de raf
|
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
|
WO2013184766A1
(en)
|
2012-06-06 |
2013-12-12 |
Irm Llc |
Compounds and compositions for modulating egfr activity
|
|
CA2871388A1
(en)
*
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
5-azaindazole compounds and methods of use
|
|
KR20150060724A
(ko)
|
2012-09-28 |
2015-06-03 |
머크 샤프 앤드 돔 코포레이션 |
Erk 억제제인 신규 화합물
|
|
EP3181564B1
(en)
|
2012-11-20 |
2019-09-18 |
H. Hoffnabb-La Roche Ag |
Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
WO2014210354A1
(en)
|
2013-06-28 |
2014-12-31 |
Genentech, Inc. |
Azaindazole compounds as inhibitors of t790m containing egfr mutants
|
|
MX2016002241A
(es)
|
2013-08-22 |
2016-05-31 |
Hoffmann La Roche |
Alcoholes de alquinilo y metodos de uso.
|
|
CN104418858B
(zh)
|
2013-08-30 |
2018-12-11 |
浙江医药股份有限公司新昌制药厂 |
2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
|
|
US9546168B2
(en)
|
2013-12-18 |
2017-01-17 |
Merck Sharp & Dohme Corp. |
ERK inhibitors
|
|
SMT202400142T1
(it)
|
2014-01-13 |
2024-05-14 |
Aurigene Oncology Ltd |
Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
|
|
CA3175724C
(en)
|
2014-03-20 |
2024-01-09 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
|
|
TWI705967B
(zh)
|
2014-03-20 |
2020-10-01 |
美商卡佩拉醫療公司 |
苯并咪唑衍生物及其醫藥組合物及使用方法
|
|
CN105315285B
(zh)
*
|
2014-07-25 |
2017-12-08 |
上海海雁医药科技有限公司 |
2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
|
|
EP3270694A4
(en)
*
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
CN108012529A
(zh)
|
2015-05-15 |
2018-05-08 |
诺华股份有限公司 |
治疗egfr突变的癌症的方法
|
|
EP3303334B1
(en)
|
2015-06-03 |
2021-06-02 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CA2987914C
(en)
|
2015-06-30 |
2022-09-13 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of egfr and methods of use thereof
|
|
KR20180051624A
(ko)
|
2015-09-11 |
2018-05-16 |
베링거 인겔하임 인터내셔날 게엠베하 |
피라졸릴 치환된 헤테로아릴 및 의약으로서의 이의 용도
|
|
TWI726968B
(zh)
*
|
2016-01-07 |
2021-05-11 |
開曼群島商Ｃｓ醫藥技術公司 |
Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
|
|
SG11201903871TA
(en)
|
2016-11-03 |
2019-05-30 |
Bristol Myers Squibb Co |
Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
|
|
CA3061053A1
(en)
|
2017-06-02 |
2018-12-06 |
Boehringer Ingelheim International Gmbh |
Anti-cancer combination therapy
|
|
PH12020550725B1
(en)
|
2017-12-02 |
2024-05-24 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
|
|
WO2019162323A1
(en)
*
|
2018-02-21 |
2019-08-29 |
Boehringer Ingelheim International Gmbh |
New benzimidazole compounds and derivatives as egfr inhibitors
|
|
WO2020178316A1
(en)
*
|
2019-03-05 |
2020-09-10 |
Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. |
5- or 7-azaindazoles as beta-lactamase inhibitors
|